Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.81 |
| ▸ | RAB9A | P51151 | 9/20 | 0.72 |
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416534 | 0.90 | S1PR1 (1.00) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12171128 | 0.86 | S1PR1 (0.67) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26004927 | 0.85 | RAB9A (0.63) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14153204 | 0.84 | NPC1 (0.62) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26004648 | 0.84 | RAB9A (0.66) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL60707 | 0.82 | RAB9A (0.67) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26004943 | 0.81 | MAPK1 (0.67) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL21105048 | 0.81 | RAB9A (0.62) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24258043 | 0.80 | S1PR1 (0.59) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26004926 | 0.80 | RAB9A (0.61) | S1PR1RAB9ANPC1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115703761-A | Compound as WWP1 inhibitor and application thereof | 首药控股(北京)股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-6486142-B2 | A,A-DIFLUOROBENZYLPHOSPHONIC ACID DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | disclosed |
| EP-1244678-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
| WO-2001046206-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PPM1B, PTPRO, PTPA | S1PR1 2885/4885RAB9A 1181/4885NPC1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.